While de novo mutations (DNMs) conferring risk in neuropsychiatric disorders have been revealed by next-generation sequencing, the role of DNMs involved in post-transcriptional regulation in pathogenesis of these disorders remains to be elucidated. By curating 42,871 DNMs from 9,772 core families with six kinds of neuropsychiatric disorders and controls, we identified 2,381 post-transcriptionally impaired DNMs (piDNMs) and prioritized 1,923 candidate casual genes in these six disorders by employing workflow RBP-Var. Our results revealed a higher prevalence of piDNM in the probands than that of controls (P = 9.52E-17).
Introduction
In the past decades, there have been increased efforts to better understand the pathogenesis of psychiatric disorders. Next-generation sequencing, which allows genome-wide detection of rare and de novo mutations (DNMs), is transforming the pace of genetics of neuropsychiatric disorder by identifying protein-coding mutations that confer risk. Despite previous studies that have analyzed the biological and clinical implications of protein truncating mutations identified from next-generation sequencing, 1,2 the risk of DNMs involved in transcriptional and post-transcriptional regulation in these disorders remain obscure.
Various computational methods have been developed to predict the effects of amino acid substitutions on protein function and to classify corresponding mutations as deleterious or benign. The majority of these approaches rely on evolutionary conservation or protein structural constraints of amino acid substitutions and focus on direct changes in protein coding genes, especially from nonsynonymous mutations which directly affect the gene product 3 . However, genetic mutations may not only impact the protein structure or catalytic activity but may also influence transcription 4,5 via direct or indirect effects on DNA-protein binding 6 , histone modifications 7 , enhancer cis-regulation 8 and gene-enhancer interactions 9 . Meanwhile, genetic mutations could impair post-transcriptional processes 10,11 such as interactions with RNA binding proteins (RBPs), mRNA splicing, mRNA transport, mRNA stability and mRNA translation.
Hitherto, previous studies of neuropsychiatric disorders have focused on genetic mutation in coding region 12 , cis-regulation [13] [14] [15] , epigenome 16 , transcriptome 17, 18 , and proteome 19, 20 , but less is pursued with regard to how these disorders interface with post-transcriptional regulation. Therefore, potential peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
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Results
Our ultimate goal was to identify all piDNMs from DNM in six neuropsychiatric disorders by analyzing a variety of aspects related to posttranscriptional regulation process. To do this, we first developed a comprehensive workflow with a statistic algorithm that links the potentially functional roles in post-transcriptional regulation to DNMs. We then used this workflow to identify functional variants from 9,772 core family with 42,871 de novo mutations associated with six neuropsychiatric disorders, including autism spectrum disorder (ASD), epileptic encephalopathy (EE), intellectual disability (ID), schizophrenia (SCZ), brain development defect (DD) and neurodevelopmental defect (NDD) as well as unaffected siblings (Supplementary Table 1) . We further presented an online tool which could rapidly annotates and classifies piDNMs, and determines their potential roles in neuropsychiatric disorders.
High occurrence of piDNM in neuropsychiatric disorders
First, we used our previously developed workflow RBP-Var 21 to identify functional piDNMs from 9,772 trios with 42,871 de novo mutations (29, 041 DNMs in probands and 13,830 DNMs in controls) across six kinds of neuropsychiatric disorders as well as their unaffected siblings (control). We determined DNMs with 1/2 categories predicted by RBP-Var as piDNMs and identified 2,381 piDNMs in probands (Supplementary Table 2 ). In detail, RBP-Var identified 1,410 piDNMs in ASD, 356 piDNMs in DD, 281 piDNMs in SCZ, 103 piDNMs in EE, 129 piDNMs in NDD and 102 piDNMs in ID while only 398 piDNMs were identified in controls groups (Supplementary Table 3 ). Interestingly, the average frequency of piDNMs in each patient in any one of six peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/175844 doi: bioRxiv preprint first posted online Aug. 13, 2017;  neuropsychiatric disorders were significantly over-represented compared with the one in controls (P = 9.52E-17, Figure 1A ). With the combined data from 9,772 trios, we also observed that probands groups have much higher odds ratio (OR) of piDNMs compared with controls in all six kinds of neuropsychiatric disorders ( Figure 1B ; Supplementary Table 4) . Dramatically, synonymous SNVs and unknown SNVs (SNVs which located in UTRs) in piDNMs were more prevalent in neuropsychiatric disorders versus controls (Supplementary Figure 1A -B), suggesting that synonymous SNVs and UTR SNVs which do not directly change the protein composition may also play crucial roles in the pathogenesis of neuropsychiatric disorders by influencing post-transcriptional regulation. Indeed, more than 50 diseases have been reported to be associated with synonymous SNVs in human genes 23 . In short, piDNMs that are linked to post-transcriptional dysregulation may contribute to the pathogenesis of these six neuropsychiatric disorders.
Robust discrimination of risk by piDNMs
Our platform RBP-Var determined the post-transcriptional dysfunction of piDNMs regardless of considering whether the DNMs give rise to protein truncating. To investigate the potential role of DNMs in different regulatory processes, we compared our RBP-Var 21 prediction tool with other three popular tools including SIFT 25, , PolyPhen2 (PPH2) 26 and RegulomeDB 24 . RBP-Var, RegulomeDB and SIFT/PPH2 were designed to evaluate the impact of mutation on post-transcriptional regulation, transcriptional regulation and protein product, respectively. We found that SIFT and PPH2 discriminated nonsynonymous/stop DNMs (P = 5.37E-62, P = 4.55E-03) and nonsynonymous/synonymous DNMs (P = 8.76E-123, P < 2.20E-16), respectively ( Figure 2A , B). However, RegulomeDB discriminated nonframeshift (P < 2.20E-16), nonsynonymous (P = 1.12E-39),
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The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/175844 doi: bioRxiv preprint first posted online Aug. 13, 2017;  splicing (P = 7.62E-04), stop (P < 2.20E-16) and synonymous (P = 3. 21E-22) DNMs rather than frameshift DNMs (P = 4.14E-01) ( Figure 2C ). Moreover, RBPVar could discriminate the deleterious DNMs on effect of frameshift (P = 1.38E-03), nonsynonymous (P = 6.31E-60), splicing (P < 2.20E-16) and synonymous (P=8.98E-09) ( Figure 2D ).
Our results indicated that both RegulomeDB and RBP-Var better distinguish deleterious DNMs from benign ones compared to SIFT and PPH2. However, the number of deleterious DNMs detected by RegulomeDB is much less than that of RBP-Var, suggesting that RegulomeDB has a higher false-negative rate than RBPVar. Therefore, we performed receiver operating characteristic (ROC) analysis to systemically evaluate the sensitivity and specificity of these four prediction methods. We found that area under curve (AUC) value of SIFT, PPH2, RBP-Var and RegulomeDB are 78.27 %, 76.57 %, 82.89 % and 50.77 %, respectively (Supplementary Figure 2) . Moreover, the AUC value of SIFT, PPH2, and RBP-Var is significantly more sensitive and specific higher than that of RegulomeDB with P value 1.63E-10, 2.40E-08 and 2.51E-60, respectively. In addition, while the AUC value of AUC value of RBP-Var is significantly higher than that of SIFT and PPH2 with p value 0.049 and 0.019, respectively. Consequently, we compared the deleterious DNMs detected by these four methods and found that RBP-Var detected more piDNMs that overlapped with predictions of SIFT and PPH2 than that of RegulomeDB. In contrast, RBP-Var could detect an additional 1,234 piDNMs that were regarded as benign DNMs by other three methods, accounting for 37.29% of total 3,309 deleterious DNMs detected by all four tools (Supplementary Figure 3) . In terms of genes related to deleterious DNMs, 909 functional genes (Supplementary Figure 4) which were determined by RBP-Var specially and the gene ontology were enriched in some neurodevelopmental peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/175844 doi: bioRxiv preprint first posted online Aug. 13, 2017;  pathways such as Notch signaling pathway (P = 9.82E-4), Neural Crest Differentiation (P = 0.0044), ErbB Signaling Pathway (P = 0.0048) and Signaling Pathways in Glioblastoma (P = 7.48E-4) (Supplementary Figure 5 ; Supplementary   Table 5 ). Whereas, the functional genes detected specifically by RBP-Var in controls were not enriched in any gene ontology. Therefore, the piDNMs detected by RBP-Var are distinct and may play significant roles in the post-transcriptional processes of the development of neuropsychiatric disorders.
Distinct features of piDNM between disorders
Our previous study using the NPdenovo database demonstrated that de novo mutations predicted as harmful in protein level are shared by four neuropsychiatric disorders 25 . Therefore, we wondered whether there were common piDNMs among six neuropsychiatric disorders. Firstly, we identified 24 genes harboring recurrent piDNMs among 2,381 piDNMs, including nine genes from ASD trios, 10 genes from DD&NDD trios, six genes from ID trios, and one genes from EE trios ( Figure   3A ; Supplementary Table 6 ). Only two genes harbored cross-disorder recurrent piDNMs. One was STXBP1 which occurred in both DD and EE, and another was CTNNB1 which occurred in both ASD and DD. However, we identified 312 genes carrying at least two piDNMs among 1,923 candidate genes (accounting for 16.22%), including 252 genes from ASD trios, 38 genes from EE trios, 40 ID trios, 68 SCZ trios and 132 genes from DD&NDD trios by RBP-Var ( Figure 3B ; Supplementary Table 7) .
Subsequently, we compared the genes harboring piDNMs across six disorders and found 214 genes significantly shared by at least two kinds of disorders rather than random overlaps (permutation test, P < 1.00E-5 based on random resampling, Figure 3C , D). Furthermore, the genes harboring piDNMs in controls also have 1 0 significantly fewer overlaps with the 214 shared genes in the six disorders than random overlaps (P = 0.007, Supplementary Figure 6A ).
In addition, the number of shared genes for any pairwise comparison is significantly higher than random overlaps (P < 0.05) except for the comparison of EE versus SCZ (P = 0.17864) (Supplementary Figure 7) . On the contrary, the genes harboring piDNMs in controls have significantly fewer overlaps with disorders than random overlaps: ASD (P < 1.00E-5, Supplementary Figure 6B ), ID (P < 1.00E-5, Supplementary Figure 6C ), EE (P = 1.20E-4, Supplementary Figure   6D ), SCZ (P < 1.00E-5, Supplementary Figure 6E ) and DD&NDD (P < 1.00E-5, Supplementary Figure 6F ). Our observation suggests that there are common genes harboring piDNMs in these six neuropsychiatric disorders.
Several neuropsychiatric disorders share many symptoms suggesting common underlying molecular mechanism exist that may implicate important regulators of pathogenesis. Thus, we performed clueGO analysis for these shared genes and found they were enriched in crucial neurodevelopmental pathways (Supplementary Table 8 ; Supplementary Figure 8 ), including thyroid hormone signaling pathway (q = 1.10E-5), modulation of synaptic transmission (q = 4.50E-5), motor activity (q = 6.10E-5), dopamine receptor binding (q = 1.80E-4), visual learning (q = 2.00E-4), cognition (q = 3.00E-4), learning or memory (q = 2.00E-3), postsynaptic density (q = 2.40E-03), regulation of GABAergic synaptic transmission (q = 5.90E-03), regulation of synaptic plasticity (q = 1.00E-2), regulation of axonogenesis (q = 2.20E-2), cell cortex (q = 2.20E-2) and regulation of oligodendrocyte differentiation (q = 4.80E-2). Intriguingly, we found some enriched epigenetic pathways, such as epigenetic regulation of gene expression (q = 3.50E-8), histone methylation (q = 4.60E-4), histone lysine methylation (q = 3.7E-3), macromolecule methylation (q = 1.10E-2), chromatin silencing (q = 1.10E-2), chromatin 1 1 remodeling (q = 1.20E-2), regulation of chromatin organization (q = 1.40E-2), chromatin-mediated maintenance of transcription (q = 1.60E-2). These epigenetic regulating genes are composed of ARID1B (P TADA = 2.29E-8), CTCF (P TADA = 2.29E-8), CTNNB1 (P TADA = 2.29E-8), EP300 (P TADA = 2.29E-8), MECP2 (P TADA = 4.58E-7), DNMT3A (P TADA = 7.33E-7), KMT2D (P TADA = 1.86E-4), MYO1E
(P TADA = 8.80E-4), CNOT1 (P TADA = 6.05E-3), TNRC18 (P TADA = 6.80E-3), JARID2 (P TADA = 1.70E-2), PHF19 (P TADA = 7.54E-2), TNRC6A (P TADA = 9.31E-2), DOT1L (P TADA = 1.68E-1), KMT2B (P TADA = 5.64E-1) (Supplementary Table   9 ). Moreover, most of these epigenetic modification genes, especially for genes with P TADA < 0.05, have been previously linked with neuropsychiatric disorders [26] [27] [28] [29] .
Interestingly, shared genes in clueGO enrichment analyses are intensive linkages among these significant pathways as some of piDNMs-containing genes could play roles in more than one of these pathways (Supplementary Figure 9) .
In contrast, we also observed hundreds of piDNM-containing genes are disorder-specific ( Figure 3C ). Follow-up GO enrichment analysis revealed that 226, four and eight GO terms were enriched for ASD, SCZ and DD&NDD from these disorder-specific genes (q < 0.05), respectively. Several GO terms are associated with neurodevelopmental defects. For example, GO terms "neurogenesis" (q = 6.70E-03) and "neuron development" (q = 2.70E-02) were enriched for ASDspecific genes (Supplementary Table 10 ). And GO terms "regulation of autophagy" (3.00E-03), "regulation of macroautophagy" (3.40E-03), "macroautophagy"
(1.60E-02) and "regulation of establishment of planar polarity involved in neural tube closure" (1.80E-02) were enriched in SCZ-specific genes (Supplementary Table 11 ). In addition, GO terms "response to UV" (q = 2.20E-3), "regulation of chromatin organization" (q = 8.50E-3), "helicase activity" (q = 1.00E-2), "histone methyltransferase complex" (q = 1.40E-02), "cellular response to UV" (q = 1.70E-peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/175844 doi: bioRxiv preprint first posted online Aug. 13, 2017;  02), "viral genome replication" (q = 1.90E-02) and "regulation of histone acetylation" (q = 2.30E-02) were enriched in DD&NDD specific genes (Supplementary Table 12 ). However, there was no enriched GO terms for ID and EE specific genes. These disorder-specific genes may point to disorder-specific phenotypes and distinctive biological processes among the six neuropsychiatric disorders.
Enriched co-expression modules
As co-expression of genes has been used to explore the common and distinct molecular mechanism in neuropsychiatric disorders 30 , we performed weighted Figure 4D ). Only two out of the 214 cross-disorder genes were not clustered in the co-expression networks (Supplementary Table 13 ). In addition, 
Intensive protein-protein interactions
The co-expression results indicated that these 214 cross-disorder proteins may have intensive protein-protein interactions (PPI). To identify common biological processes that potentially contribute to disease pathogenesis, we established protein-protein interactions within these 214 cross-disorder genes by investigating protein-protein interactions curated in database BioGRID. Surprisingly, 128 out of 214 (59.81%) cross-disorder genes represent an interconnected network on the level of available direct/genetic protein-protein interactions ( Figure 5A ). In
addition, an overwhelming majority (98.54%, 203 out of 206 pairs) of the proteinprotein interactions constitute direct interactions while only 3 interaction pairs are genetic interactions (Supplementary Table 17 ). Furthermore, we determined several crucial hubs of protein-protein interactions, including CUL3, CTNNB1, HECW2, HNRNPU, EP300, SMARCA4, ARRB2, PTPRF, MYH9 and NOTCH1
( Figure 5A ), which may control common biological processes among these six neuropsychiatric disorders. Indeed, these 128 cross-disorder proteins are enriched in nervous system phenotypes, including abnormal synaptic transmission, abnormal nervous system development, abnormal neuron morphology and abnormal brain morphology, and behavior/neurological phenotype such as abnormal motor coordination/balance (two sided Fisher's Exact Test, q < 0.05, Supplementary Figure 14A ). Similarly, these 128 genes in interaction network are enriched in nervous system phenotype including abnormal nervous system development and abnormal brain morphology (two sided Fisher's Exact Test, q < 0.05, Supplementary Figure 14B ). Dramatically, HNRNPU belongs to the subfamily of ubiquitously expressed heterogeneous nuclear ribonucleoproteins (hnRNPs) which are RNA binding proteins and they form complexes with heterogeneous nuclear RNA (hnRNA). These proteins are associated with premRNAs in the nucleus and appear to influence pre-mRNA processing and other aspects of mRNA metabolism and transport.
To investigate the expression of these co-interacting genes in the human cortex of ASD patients and normal donators, we downloaded and compared the normalized FPKM value from Gene Expression Omnibus (GEO) with accession number GSE64018 and GSE76852, respectively. We identified 97 significantly differential expression genes (accounting for 75.78% of the PPI genes) between ASD patients and normal controls (Student's t-test, q < 0.05, Figure 5B ). And 86 of peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/175844 doi: bioRxiv preprint first posted online Aug. 13, 2017;  these PPI genes were highly expressed in ASD patients while only 11 genes were down-regulated in ASD patients when compared with normal controls (Supplementary Table 18 ), implying that most of these PPI genes were abnormally expressed in ASD patients.
Shared networks between piDNM and RBPs
According to previous studies, dysregulation or mutations of RBPs can cause a range of developmental and neurological diseases [33] [34] [35] . 
The PostOmics database
The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/175844 doi: bioRxiv preprint first posted online Aug. 13, 2017;  To make our findings easily accessible to the research community, we have developed RBP-Var2 platform (http://www.rbp-var.biols.ac.cn/) for storage and retrieval of piDNMs, candidate genes, for exploring the genetic etiology of neuropsychiatric disorders in post-transcriptional regulation.
Discussion
In this study, we systematically analyzed the damaging effect of de novo mutations at the level of post-transcriptional regulation in six neuropsychiatry disorders. We discovered 2,381 piDNMs that were extremely deleterious on posttranscriptional regulation, of which 1,034 (43.43%) piDNMs were extremely deleterious (predicted by NPdenovo) on the structure and function of protein.
Among the total 1,923 genes containing piDNMs, 862 (44.83%) genes were predicted to simultaneously alter the structure and function of correspondingly coded proteins. On the other hand, 1007 out of 2672 (37.69%) genes and 1023 of 3714 (27.54%) extreme DNMs predicted by NPdenovo were also extremely deleterious predicted by RBP-Var. Our observations indicate that over half of piDNMs are not expect to affect the structure and function of protein but are predicted to affect post-transcriptional regulation, and vice versa. Moreover, probands have higher odds ratio of piDNMs than controls in all kinds of neuropsychiatric disorders. Therefore, piDNMs are one of major contributors to etiology for neuropsychiatry disorders.
We applied RBP-Var algorithm to annotate and interpret de novo variants in subjects with six neuropsychiatry disorders and control subjects. We observed a strong enrichment of pathogenic or likely pathogenic variants in affected subjects.
In comparison with accuracy of RBP-Var (82.89%), other prediction algorithms such as SIFT or PPH2 have comparative accuracy (76~78%) while RegulomeDB peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
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This observation suggests that the potential pathogenicity of genetic variants is mainly due to post-transcriptional dysregulation and malfunction of protein, but not disruption of transcription process. Therefore, deciphering multiple biological layers of deleteriousness, particularly post-transcriptional regulation and structure/function of protein, may improve the accuracy of algorithm's prediction.
To date, it has been a challenge to estimate the deleteriousness of synonymous Most interestingly, we discovered some enriched epigenetic pathways, such as those that regulate gene expression and histone methylation. This finding is consistent with a previous report that demonstrated that more than 68% of ASD cases shared a common acetylome aberrations at >5,000 cis-regulatory regions in prefrontal and temporal cortex 43 . Such common "epimutations" may be induced by either perturbations of epigenetic regulations (including post-transcriptional peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/175844 doi: bioRxiv preprint first posted online Aug. 13, 2017;  regulations) due to genetic mutations of substrates or the disruptions of epigenetic modifications due to the genetic mutation of epigenetic genes. Actually, our observations suggest that alterations of "epimutations" were associated with the dysregulation of post-transcription. In fact, we found several recurrent piDNMcontaining genes including CHD8, CHD2, SYNGAP1, ADNP, POGZ, ANK2 and DYRK1A, are non-epigenetic genes. Moreover, we also discovered several recurrent epigenetic genes including KMT2A, KMT2B, KMT2C, KAT6B, KDM3B, JARID2, DNMT3A and MECP2, that contain piDNMs which may play important roles in the genome-wide aberrations of epigenetic landscapes through disruption the post-transcription regulation. Furthermore, WGCNA analysis revealed that major hubs of the co-expression network for these 214 piDNMcontaining genes were histone modifiers by using BrainSpan developmental transcriptome. These data indicate that piDNM-containing genes are co-expressed with genes frequently involved in epigenetic regulation of common cellular and biological process in neuropsychiatric disorders.
Importantly, these 214 piDNMs-containing genes harbor intensive proteinprotein interactions in physics and shared regulatory networks between piDNMs and RBPs in six neuropsychiatric disorders. We identified several RBP hubs of regulatory networks between piDNMs-containing genes and RBP proteins, including EIF4A3, FMRP, PTBP1, AGO1/2, ELAVL1, IGF2BP1/3, WDR33 and FXR2. Taking FMRP for example, it is a well-known pathogenic gene of Fragile X syndrome which co-occurs with autism in many cases and its targets are highly peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
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Materials and methods

Data collection.
For this study, 9,772 trios were recruited from previous WES/WGS studies, comprising 7,453 parent-probands trios associated with six neuropsychiatric disorders and 2,319 control trios. After deduplication, a total of 29,041 DNMs in probands and 13,830 DNMs in controls were identified for subsequent analysis.
Identification of deleterious piDNMs and comparison with variants
predicted by other methods. RegulomeDB were used to analyze the same dataset of DNMs as the input for RBP-Var. We only kept the mutations qualified as "damaging" from the result of SIFT and "possibly damaging" or "probably damaging" from PolyPhen2. In the case of RegulomeDB, mutations labelled as category 1 and 2 were retained. Next, we classified the type of mutation (frameshift, nonframeshift, nonsynonymous, synonymous, splicing and stop) and located regions (UTR3, UTR5, exonic, ncRNA exonic and splicing) in order to determine distribution of piDNMs, genetic variants and other regulatory variants. The number of variants in cases versus controls was illustrated by bar chart (***: P < 0.001, **: 0.001 < P < 0.01, *: 0.01 < P < 0.05, binomial test).
TADA analysis of DNMs in six disorders
The TADA program (Transmission And De novo Association), which predicts risk genes accurately on the basis of allele frequencies, gene-specific penetrance, and mutation rate, was used to calculate the P-value for the likelihood of each gene contributing to the all six disorders with default parameters. 
ROC curves and specificity/sensitivity estimation
Overlaps of piDNMs between disorders.
In order to elucidate the overlap of genes among any two of the six disorders as well as each disorder and the control, we shuffled the intersections of genes and repeated this procedure 100,000 times. During each permutation, we randomly selected the same number of genes as the actual situation from the entire genome for each disorder and the control, then p values were calculated as the proportion of permutations during which the observed number of genes was above/below the number of genes in simulated situations.
Functional enrichment analysis
The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/175844 doi: bioRxiv preprint first posted online Aug. 13, 2017;  A gene harboring piDNMs would be selected into our candidate gene set to conduct functional enrichment analysis if it occurred in at least two of the six disorders. GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichments analysis was implemented by Cytoscape (version 3.4.0) plugin ClueGO (version 2.3.0) and P values calculated by hypergeometric test was corrected to be q values by Benjamini-Hochberg procedure for reducing the false discovery rate resulted from multiple hypothesis testing.
Co-expression and spatiotemporal specificity
Normalized gene-expression of 16 human brain regions were determined by RNA sequencing and obtained from BrainSpan (http://www.brainspan.org).
Expression for 206 out of 214 extreme damaging cross-disorder genes was extracted and clustered according to their expression pattern by using R-package WGCNA (weighted correlation network analysis). The expression level for each gene and development stage (only stages with expression data for all 16 structures were selected, n = 14) was presented across all brain regions.
Protein-protein interaction and phenotype enrichment
Cross-disorder genes containing piDNMs were subjected to esyN analysis for generating a network of protein interactions and the network of protein interaction was created by using physical and genetic interactions of H. sapiens curated in 
Gene-RBP interaction network
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